Pluristem Therapeutics Inc.Find Ratings Reports
PLURISTEM THERAPEUTICS INC's gross profit margin for the second quarter of its fiscal year 2018 has significantly decreased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing net income growth, but not when comparing revenue growth.
At the same time, stockholders' equity ("net worth") has greatly increased by 47.17% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY18||Q2 FY17|
|Net Sales ($mil)||0.05||0.0|
|Net Income ($mil)||-8.23||-6.61|
|Balance Sheet||Q2 FY18||Q2 FY17|
|Cash & Equiv. ($mil)||35.86||21.94|
|Total Assets ($mil)||44.73||32.3|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q2 FY18||Q2 FY17|
|Gross Profit Margin||-16004.0||0.0|
|Return on Assets||-68.16||-81.55|
|Return on Equity||-82.5||-104.88|
|Debt||Q2 FY18||Q2 FY17|
|Share Data||Q2 FY18||Q2 FY17|
|Shares outstanding (mil)||109.34||81.31|
|Div / share||0.0||0.0|
|Book value / share||0.34||0.31|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||322691.0||479273.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 3.61 indicates a premium versus the S&P 500 average of 3.15 and a significant discount versus the industry average of 22.16. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, PLURISTEM THERAPEUTICS INC seems to be trading at a premium to investment alternatives within the industry.
|PSTI NM||Peers 42.18||PSTI NM||Peers 28.08|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
PSTI's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PSTI's P/CF is negative making the measure meaningless.
|PSTI NM||Peers 60.15||PSTI NA||Peers 0.38|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
PSTI's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PSTI 3.61||Peers 22.16||PSTI 3.04||Peers -3.51|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PSTI is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
PSTI is expected to have an earnings growth rate that significantly exceeds its peers.
|PSTI 2667.85||Peers 58.17||PSTI NA||Peers 586.99|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PSTI is trading at a significant premium to its industry.
Neutral. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.
The growth rate for PSTI is not available.